Arrow Therapeutics

Kymab Ltd. CEO Dr David Chiswell OBE has more than 30 years of experience in the biotechnology industry, having co-founded Cambridge Antibody Technology Group PLC in 1990, a company that origina

A look at financing, M&A, and alliance activity January-March 2007 In this issue, we present another installment of our quarterly review of dealmaking—for January-March 2007. Our data comes from Windh

David Brennan has sharpened AstraZeneca’s therapeutic area focus and embraced external R&D. The next two years will determine whether the productivity drive is working—or if more radical change is nee

For Big Pharma, partnering 50% of a potential blockbuster in Phase III was hard to fathom only a few years ago. BMS and AZ’s diabetes deal demonstrates that not all big drugmakers are moving in the sa